Leukemia cell lines | Classifications | Clinical Status | Survival* (months) | Kayotypes |
---|---|---|---|---|
BA25** | B-ALL (L3) | Relapse-1/refractory | 1.3 | 45, xy, t(2;8)(p12;q24),-4,+7,-10, idemx2; 44-47, t(2:8)(p23, q24) |
BA78** | B-ALL (L3) | Relapse-1/refractory | 0.4 | 45-47, XY, t(8;14)(q24, q32),-16 +1 |
BA91 | B-ALL (L3) | relapse-1 | 4.5 | 45-46, XY, t(8;14)(q24, q32), -9, t(11;18)(q13;p11), +14, -16, +mar1, +mar2, +mar3 |
BA127 | Pre-B-ALL (L1) | relapse-2 | 0.8 | nd |
TA7** | T-ALL (L1) | relapse-1 | 6.0 | 46, XY |
TA27 | T-ALL (L1) | relapse-1/refractory | 3.0 | 46, XY |
TA83 | T-ALL (L1) | relapse-2/refractory | 1.5 | 46, XY, del(9)(p21), -7, t(11;14)(p13;q11.2) -7 |
MA120** | AML (M2) | relapse-2/refractory | 2.5 | 46, XY, del (16)(q13q22), dup(1) (q44q25) |
MA126 | AML (M4) | secondary leukemia | 1.1 | 46, XY, t(9;11)(p21, q23) |